Bristol Myers Squibb has signed a major deal with China’s largest pharmaceutical company, Hengrui Medicine. Valued at up to $15.2 billion, this agreement focuses on early-stage drug programs across cancer, blood disorders, and immune diseases. The timing coincides with looming patent expirations that threaten revenue streams for big pharma firms worldwide. Why the Deal Matters